Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Non-comparative Phase II Open Study Evaluating the Efficacy of a Reduced Dose Atazanavir / Ritonavir 200/100 mg + 2 NRTI in HIV-1-infected Patients With Virological Success With Atazanavir / Ritonavir 300/100 mg + 2 NRTI

NCT02473328 is registered in ClinicalTrials.gov with Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida as lead sponsor.

NCT NCT02473328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02473328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Non-comparative Phase II Open Study Evaluating the Efficacy of a Reduced Dose Atazanavir / Ritonavir 200/100 mg + 2 NRTI in HIV-1-infected Patients With Virological Success With Atazanavir / Ritonavir 300/100 mg + 2 NRTI
Lead sponsor
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2015
Completion date
December 31, 2017
Enrollment
90 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1 infection